News
Public · Published
Corxel Secures $300 Million Private Investment to Go Public via Amanat Acquisition
Corxel Pharmaceuticals plans to go public by merging with blank-check company Amanat Acquisition. The deal includes an oversubscribed $300 million private investment from healthcare funds and is expected to provide $377 million in gross proceeds to fund operations through 2029.
Published:
Updated:
What happened
Corxel Pharmaceuticals plans to go public by merging with blank-check company Amanat Acquisition. The deal includes an oversubscribed $300 million private investment from healthcare funds and is expected to provide $377 million in gross proceeds to fund operations through 2029.
Confirmed
Global impact / market context
The cash lets Corxel fund global phase 3 trials of its once-daily oral obesity pill without relying on public markets right away. For Amanat shareholders, the deal turns a shell company into an obesity-drug developer with several years of funded operations.
Analyst inference
The raise by a clinical-stage obesity drugmaker signals investors still fund oral weight-loss treatments that could compete with injectable drugs. A merger with a blank-check company, which is a listed shell formed to buy a private business, is the chosen route to public markets.
Analyst inference
What to watch
- The transaction is expected to close in the first half of 2027, so the merger and the private investment face a long wait before completion. Confirmed
- Corxel plans global phase 3 trials of CX11, its once-daily GLP-1 pill, after alignment with the Food and Drug Administration, and a phase 1b study of higher doses should yield data in the first half of next year. Confirmed
- Only Corxel US and its obesity portfolio join Amanat; Corxel HK and JX10 stay private, so public investors get a narrower set of assets than the whole company. Analyst inference
Evidence
- Original source link unavailable